These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Development of new vaccines against dengue fever and Japanese encephalitis. Kinney RM; Huang CY Intervirology; 2001; 44(2-3):176-97. PubMed ID: 11509879 [TBL] [Abstract][Full Text] [Related]
3. From the World Health Organization. Development of dengue and Japanese encephalitis vaccines. Brandt WE J Infect Dis; 1990 Sep; 162(3):577-83. PubMed ID: 1696952 [No Abstract] [Full Text] [Related]
4. Empirically derived live-attenuated vaccines against dengue and Japanese encephalitis. Saluzzo JF Adv Virus Res; 2003; 61():419-43. PubMed ID: 14714439 [No Abstract] [Full Text] [Related]
5. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens. Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114 [TBL] [Abstract][Full Text] [Related]
6. The chimeric Japanese encephalitis/Dengue 2 virus protects mice from challenge by both dengue virus and JEV virulent virus. Yang J; Yang H; Li Z; Lin H; Zhao Y; Wang W; Tan S; Zeng X; Li Y Protein Cell; 2017 Mar; 8(3):225-229. PubMed ID: 28124229 [No Abstract] [Full Text] [Related]
7. Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs)--a novel approach to the protection of humans. Becker Y Virus Genes; 1994 Sep; 9(1):33-45. PubMed ID: 7871759 [TBL] [Abstract][Full Text] [Related]
8. Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice. Konishi E; Terazawa A; Fujii A Vaccine; 2003 Sep; 21(25-26):3713-20. PubMed ID: 12922102 [TBL] [Abstract][Full Text] [Related]
9. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Chambers TJ; Tsai TF; Pervikov Y; Monath TP Vaccine; 1997 Oct; 15(14):1494-502. PubMed ID: 9330458 [No Abstract] [Full Text] [Related]
10. A field trial of Japanese encephalitis vaccine produced in Thailand. Rojanasuphot S; Charoensuk O; Kitprayura D; Likityingvara C; Limpisthien S; Boonyindee S; Jivariyavej V; Ugchusak K Southeast Asian J Trop Med Public Health; 1989 Dec; 20(4):653-4. PubMed ID: 2561722 [No Abstract] [Full Text] [Related]
12. Vectors expressing chimeric Japanese encephalitis dengue 2 viruses. Wei Y; Wang S; Wang X Acta Virol; 2014; 58(4):340-7. PubMed ID: 25518715 [TBL] [Abstract][Full Text] [Related]
13. Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice. Konishi E; Terazawa A; Imoto J Vaccine; 2003 May; 21(17-18):1826-32. PubMed ID: 12706666 [TBL] [Abstract][Full Text] [Related]
15. Construction and preliminary investigation of a novel dengue serotype 4 chimeric virus using Japanese encephalitis vaccine strain SA14-14-2 as the backbone. Li Z; Yang H; Yang J; Lin H; Wang W; Liu L; Zhao Y; Liu L; Zeng X; Yu Y; Li Y Virus Res; 2014 Oct; 191():10-20. PubMed ID: 25091563 [TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin response and viremia in dengue-vaccinated gibbons repeatedly challenged with Japanese encephalitis virus. Edelman R; Nisalak A; Pariyanonda A; Udomsakdi S; Johnsen DO Am J Epidemiol; 1973 Mar; 97(3):208-18. PubMed ID: 4348246 [No Abstract] [Full Text] [Related]
17. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Chang GJ; Hunt AR; Holmes DA; Springfield T; Chiueh TS; Roehrig JT; Gubler DJ Virology; 2003 Feb; 306(1):170-80. PubMed ID: 12620809 [TBL] [Abstract][Full Text] [Related]
18. A novel dengue virus serotype 1 vaccine candidate based on Japanese encephalitis virus vaccine strain SA14-14-2 as the backbone. Yang H; Li Z; Lin H; Wang W; Yang J; Liu L; Zeng X; Wu Y; Yu Y; Li Y Arch Virol; 2016 Jun; 161(6):1517-26. PubMed ID: 26976137 [TBL] [Abstract][Full Text] [Related]
19. Japanese B encephalitis vaccine. Time for a reappraisal? Ruff TA Med J Aust; 1994 Oct; 161(8):511. PubMed ID: 7802832 [No Abstract] [Full Text] [Related]
20. Antibody to the nonstructural protein NS1 of Japanese encephalitis virus: potential application of mAb-based indirect ELISA to differentiate infection from vaccination. Shu PY; Chen LK; Chang SF; Yueh YY; Chow L; Chien LJ; Chin C; Lin TH; Huang JH Vaccine; 2001 Feb; 19(13-14):1753-63. PubMed ID: 11166901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]